Dr. Reddy's Laboratories to Sell Entire Shareholding of Wholly Owned Subsidiary Svaas Wellness Limited
Dr. Reddy's Laboratories Limited announced on April 7, 2026, that it has entered into an agreement for the sale of its entire shareholding in its wholly owned subsidiary, Svaas Wellness Limited. Upon the completion of this transaction, Svaas Wellness Limited will cease to be a wholly owned subsidiary of the company.The sale details provide an overview of the financial aspects and the identity of the buyer. The consideration received from the disposal amounts to INR 2.23 Cr.
The transaction was executed with Enspirit Technology Services Private Limited. The buyer is registered at 3-6-465, Flat 206, Legend Siddhi, Street 5, Himayathnagar, Hyderabad - 500029, Telangana, India, and is not affiliated with the Promoter or Promoter group of Dr. Reddy's Laboratories Limited.
The turnover of Svaas Wellness Limited for the fiscal year 2025, based on audited financials, was Rs. 28.5 Crore, with 100% of the turnover originating from Dr. Reddy's Laboratories Limited, which represented approximately 0.09% of the consolidated turnover.
Transaction Summary
The following table outlines the key parameters of the proposed sale of the subsidiary's shares:| Particulars | Details |
|---|---|
| Date Agreement Entered | April 7, 2026 |
| Expected Completion Date | April 7, 2026 |
| Consideration Received | INR 2.23 Cr |
| Buyer | Enspirit Technology Services Private Limited |
The company confirmed that this transaction does not constitute a related party transaction, as Enspirit Technology Services Private Limited is not a related party of Dr. Reddy's Laboratories Limited or any of its subsidiaries. Furthermore, the sale is not considered a related party transaction and the transaction is stated not to fall within the Scheme of Arrangement.
DRREDDY Stock Price Movement
Shares of Dr. Reddy's Laboratories Limited today slipped by 1.63% to settle at ₹1196.1 in post-market trading. The stock's activity was marked by a total traded volume of 2.33 million shares.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.